PURCHASE, NY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that Chuck Divita, chief executive officer, and Mala Murthy, chief financial officer, will participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 4:30 p.m. PT (7:30 p.m. ET). A live audio webcast and replay of the presentation will be available at https://ir.teladochealth.com/news-and-events/events-and-presentations.
About Teladoc Health
Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com.
Investors:
Michael Minchak
617-444-9612
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$9.99 |
| Daily Change: | 0.06 0.60 |
| Daily Volume: | 4,122,613 |
| Market Cap: | US$1.720B |
November 25, 2024 October 30, 2024 July 31, 2024 July 16, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
